Introduction
Cutaneous T-cell lymphomas (CTCLs) comprise a wide spectrum of heterogeneous lymphoproliferative disorders characterized by clonal expansion of neoplastic T lymphocytes in the skin. 1 Mycosis fungoides (MF) and its leukemic variant, Sezary syndrome, are the two major clinical variants of CTCL. 2 In the initial phase, which can last several years, MF presents itself as flat erythromatous skin patches, resembling chronic inflammation seen in psoriasis, eczema and chronic skin infections. In later stages, MF lesions form plaques and overt tumors, and eventually disseminate to lymph nodes and internal organs. 1, 2 Biopsies obtained from CTCL patients exhibit stage-dependent increase in angiogenesis. At the patch stage, the mean microvessel area is not significantly different from control skin, whereas both plaque and tumor stages have significantly increased microvessel areas. Interstage comparisons show that the microvessel area increases in parallel with disease progression; that is, the value of the mean microvessel area in the plaque stage is significantly higher than the value for the patch stage, and the value for the tumor stage is significantly higher than that of the plaque stage. 3, 4 Thus, increased angiogenesis is likely to be important for the pathophysiology and progression of CTCL. However, the molecular mechanisms responsible for increased angiogenesis in CTCL are unknown.
Vascularization of neoplastic tissue is induced by a switch in the balance of angiostatic and angiogenic factors released by the tumor cells. 5 Many angiostatic and angiogenic factors have been characterized, but much evidence points towards a central role of the highly potent angiogenic protein, vascular endothelial growth factor (VEGF), in tumor-associated angiogenesis. 6 In tumors, aberrant regulation of multiple signaling pathways is often found to act in concert to trigger VEGF synthesis, seemingly in a cell-and tissue-type specific manner. 7 , 8 Here we demonstrate that malignant CTCL T cells express VEGF and that this expression is promoted by aberrant activation of Janus kinase 3 (Jak3) and the c-Jun N-terminal kinases (JNKs). VEGF expression was detectable even in the early stages of the disease, suggesting that VEGF plays an important role in both the early angiogenesis and the later progression of CTCL. Inhibition of VEGF-inducing pathways or neutralization of VEGF itself could represent novel strategies in the treatment of CTCL.
Materials and methods

Antibodies and reagents
Antibodies (Abs) against activator protein (AP)-2 (C-18), c-Jun (H-79), phospho-c-Jun (KM-1), glutathione-S-transferase (GST) (Z-5), extracellular signal-regulated protein kinase (Erk1/2) (K-23), Janus kinase 3 (Jak3) (C-21), specificity protein 1 (Sp1) (PEP2), Sp3 (D-20) and VEGF (A-20) were from Santa Cruz Biotechnology ((SC) Santa Cruz, CA, USA). Abs against signal transducer and activator of transcription 3 (Stat3) were obtained from SC (C-20) and Cell Signaling Technology (#9132) (Beverly, MA, USA). The phospho-Stat3(Y705) monoclonal antibody (mAb) was from nanoTools (Denzlingen, Germany), whereas the hypoxia-inducible factor 1a (HIF-1a) mAb (#610958) was from Becton Dickinson (Franklin lakes, NJ, USA). CoCl 2 and dimethylsulfoxide (DMSO) were from Sigma (St Louis, MO, USA). The Jak3 inhibitors JAK3I1 (WHI-P131) and JAK3I2 (WHI-P154) were purchased from Calbiochem (San Diego, CA, USA). Curcumin, Sp600125, Ag490, Ag1478, SB203580 and phorbol 12-myristate 13-acetate (PMA) were from Alexis (Laufelfigen, Switzerland). Stat3 and nonspecific control SMARTpool siRNA were purchased from Upstate (Charlottesville, VA, USA). Full-length Stat3, a generous gift from Koichi Nakajima, was inserted into a pGEX-4T vector (Amersham, Little Chalfont, UK) using EcoRI and NotI restriction enzymes. XL-1 blue cells were transformed with the resulting pGEX-4T-Stat3 vector and GST-Stat3 protein expression induced with IPTG. Finally, GST-Stat3 was purified using a RediPack GST Purification module according to the manufacturer's instructions (Amersham).
Cell lines and cell culture
The malignant cell lines MyLa2000 (MF2000) and MyLa3675 (MF3675) and the non-malignant cell lines MyLa1928 (MF1928) (from skin) and MyLa1885 (MF1885) (from blood) were obtained from a plaque biopsy of a single patient with MF. 9 The PB2B cell line was derived from a patient who had a progressive cutaneous T-cell lymphoproliferative disorder. 10, 11 The SeAx cell line was established from the peripheral blood of a patient diagnosed with Sezary syndrome.
12 MF2000 and PB2B were grown in conditional media (CM) (RPMI 1640, 2 mM L-glutamine and 100 mg/ml penicillin/streptomycin; all from Sigma) supplemented with 10% fetal bovine serum (Life Technologies, Roskilde, Denmark). The MF3675 and SeAx cell lines were grown in CM supplemented with 10% pooled human serum (HS) (Blood Bank, State University Hospital, Copenhagen, Denmark) and 10 3 U/ml interleukin (IL)-2 (Proleukin) (Chiron, Emeryville, CA, USA). The MF1928 and MF1885 cells lines were grown in the same media as MF3675 and SeAx except that 25 ng/ml IL-4 (Leinco, St Louis, MO, USA) was added. Peripheral blood T (PB-T) cells were cultured in CM supplemented with 10% HS, 10 3 U/ml IL-2 and 5 mg/ml PHA-M (Roche, Basel, Switzerland). Cells grown in media containing cytokines were starved in cytokine-free media before experimental use.
Patients
Thirty-five patients suffering from different stages of CTCL were included in the retrospective in situ analysis. All patients were tended by the Cutaneous Lymphoma Clinic at the Department of Dermatology, University of Wü rzburg. Both paraffin-embedded and cryopreserved tissue samples were used for analysis. All lesions were obtained by surgical excision for diagnostic purposes and immediately after excision were fixed in formalin or stored in liquid nitrogen. Only tissue sections not needed for diagnosis were used for these analyses. Informed consent was obtained from all patients before any of these measures. For tissue samples representing early lesions, the diagnosis of CTCL had been confirmed in the follow-up of the patient.
Immunohistochemistry
The formalin-fixed, paraffin-embedded tissue sections were deparaffinized in xylol, rehydrated in graded alcohol and washed with aqua bidestilata. For antigen retrieval of VEGF after formalin fixation, slides were overlaid with prewarmed antigen retrieval solution of pH 9 (S2367, DAKO, Hamburg, Germany), followed by incubation in saturated steam for 20 min. After cooling to room temperature, slides were washed with aqua bidestilata. For staining, slides were incubated with the polyclonal rabbit anti-VEGF antibody at a final dilution of 1:100 for 1 h, washed with buffer once and then exposed to the Multi Link Biotin Kit (K0690, DAKO) for 25 min. Slides were then again washed with buffer, before endogenous peroxidase was blocked with peroxidase blocking solution (K0690, DAKO) for 10 min. After an additional washing step, slides were subjected to streptavidin-horseradish peroxidase (HRP) for 25 min (K0690, DAKO), followed by another washing step. Next, slides were stained with Vector Nova Red for 15 min. Following one wash with aqua bidestilata, slides were counterstained with hemalaun, washed with aqua bidestilata and overlaid in grading alcohol, xylol and finally mounted in Hypermount (Shandon, Pittsburgh, PA, USA).
Enzyme-linked immunosorbent assay
Cells (1 Â 10 6 cells/sample) were washed extensively and resuspended in 800 ml fresh cytokine-free media in a 12-well plate. Subsequently, the cells were incubated for 6 or 24 h, as stated, with or without the given concentrations of inhibitors. Finally, the supernatant was harvested and the concentration of VEGF measured by enzyme-linked immunosorbent assay (ELISA) using a Human VEGF ELISA Development Reagent Kit (V107) purchased from Leinco. ELISA determinations were preformed with triplicate cultures.
Protein extraction and Western blotting
Cells were rapidly pelleted and lysed in ice-cold lysis buffer (1% NP-40, 20 mM TRIS-HCl pH 8.0, 140 mM NaCl, 10% glycerol and the following inhibitors: 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM Na 3 VO 4 , 10 mM NaF, 1 mM iodioacetamide, 5 mM ethylenediaminetetraacetic acid (EDTA) and 7.5 mg/ ml aprotinin) for 30 min on ice. Total cell lysates were boiled in reducing sodium dodecyl sulfate (SDS) sample buffer and subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by electrophoretic transfer to a nitrocellulose (NC) membrane. Afterwards, the NC membrane was blocked with 3% milk in PBS-T for 1 h and then incubated with primary Abs overnight. Subsequently, the NC membrane was incubated with HRP-conjugated secondary Abs for 1 h (DAKO). Blots were evaluated using enhanced chemiluminescence (ECL) and stripped according to the manufacturer's instructions (Amersham). To ensure equal loading, the total protein concentration of each sample was determined by Bio-Rad Protein Assay (#500-0001) (Bio-Rad, Hercules, CA, USA).
Non-radioactive Jak3 kinase assay 20 Â 10 6 cells per sample were incubated in cytokine-free media with 50 mg/ml JAK3I1 or vehicle for 2 h. Next, the cells were lysed in 900 ml RIPA lysis buffer (50 mM TRIS-HCl pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40 and 1 mM EDTA containing 1 mM PMSF) for 30 min on ice. Lysates were precleared for 3 h with protein A-agarose beads before overnight incubation with rabbit anti-Jak3 or rabbit anti-Erk1/2 Abs. Ab-protein complexes were recovered by incubation with protein A agarose beads for 3 h and washed extensively with RIPA lysis buffer and kinase buffer (20 mM PIPES pH 7.0, 3 mM MnCl 2 ). Then, kinase assay mix (kinase buffer containing 1.2 mM ATP with or without 140 mg/ml GST-Stat3) was added and the samples incubated for 4 h with constant agitation at room temperature. Finally, the samples were boiled in reducing SDS sample buffer and subjected to SDS-PAGE and Western blotting.
Transient transfections
Transient transfections were performed essentially as described previously 13 using 0.1 nmol Stat3 or nonspecific control small interfering RNA (siRNA) and 2 Â 10 6 cells.
Oligonucleotide affinity purification
When chemical enzyme inhibitors were used, cells were preincubated in their respective cytokine-free media with the given concentrations of inhibitors or vehicle for 2 h. Likewise, when PMA was used, cells were pre-incubated with 10 ng/ml PMA or vehicle for 20 min. The cells were lysed in 900 ml lysis buffer and lysates precleared for 3 h with avidin-agarose beads followed by overnight incubation with 225 pmol of the respective biotinylated DNA oligonucleotides (bio-oligos). The bio-oligo-protein complexes were precipitated by incubation with avidin-agarose beads for 3 h and subsequently extensively washed with lysis buffer. Subsequently, the samples were boiled in reducing SDS sample buffer and analyzed by Western blotting. The following bio-oligos were used: Sp1/Sp3 bio-oligo
JNK kinase assay
Initially, the cells were incubated with the given amounts of inhibitors or vehicle for 2 h. Subsequently, they were rapidly pelleted and lysed in JNK kinase assay lysis buffer (20 mM TRISHCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM ethylenegylcol tetraacaetate, 1% Triton X-100 containing the inhibitors: 2.5 mM Na-pyrophosphate, 1 mM NaF, 1 mM NaVO 4 and 0.5 mM PMSF) for 30 min on ice. Then, the total JNK concentration and activity of each sample were measured. The JNK concentration was determined using a pan JNK ELISA kit (DYC1205) (R&D Systems, Minneapolis, MN, USA) in accordance with the manufacturer's instructions. To determine the JNK activity, lysates were incubated with 20 ml c-Jun fusion protein beads (#9811) (Cell Signaling Technology) overnight. Next, the beads were washed extensively first with ice-cold JNK kinase assay lysis buffer and then with JNK kinase assay buffer (25 mM TRIS-HCl pH 7.5, 10 mM MgCl 2 ). After the final wash, the beads were incubated with 25 ml kinase assay mix (JNK kinase assay buffer with 0.135 mM NaVO 4 , 2 mM DTT, 50 mM ATP) containing 5 mCi of [g-32 P]ATP (Amersham) for 30 min at 301C. Finally, the samples were boiled in reducing SDS sample buffer, subjected to SDS-PAGE and blotted to an NC membrane. The NC membrane was analyzed using a Typhoon 9410 scanner (Amersham) and ImageMaster TotalLab software (Amersham).
Results
VEGF expression in CTCL
To determine the capacity of malignant CTCL T cells to induce angiogenesis, we initially compared mRNA expression of angiogenic factors in malignant and non-malignant T cells. The level of VEGF mRNA was significantly increased in the malignant T cells in contrast to mRNA levels of other angiogenic factors including bFGF, PDGF, EGF and angiopoietin 1 and 2 (data not shown). The spontaneous production of VEGF was confirmed at the protein level using a VEGF-specific ELISA. All the malignant CTCL T-cell populations examined secreted VEGF, whereas non-malignant T cells from a CTCL patient and PB T cells from a healthy donor did not (Figure 1a ). To address whether VEGF expression is also found in vivo, we examined the VEGF expression in specimens from 35 patients with early-and late-stage CTCL (Figure 1b VEGF in CTCL T Krejsgaard et al Table 1 ). As shown in Figure 1b , dermal infiltrates of MF lesions showed frequent and intense staining with anti-VEGF Ab, indicating a constitutive, high production of VEGF in vivo. Importantly, VEGF was detected even in early lesions, indicating that VEGF production is an early event in CTCL progression (Figure 1b and Supplementary Table 1) .
VEGF production correlates with constitutive activity of Jak3 but not Stat3
Analyses of the VEGF gene promoter have identified a number of potential binding sites for various transcription factors, consistent with the identified complexity of VEGF transcriptional regulation. 7, 8 Among these, HIF-1, AP-1, AP-2, Sp1, Sp3 and Stat3 appear to play key roles in the regulation of VEGF transcription and expression (Figure 2) . 7, [14] [15] [16] [17] [18] Stat3 is constitutively active in CTCL and circumstantial evidence suggests that Jak3 or Jak3-like kinases mediate this activation. 13, 19, 20 Therefore, we first focused on the possible involvement of the Jak3/Stat3 signaling pathway in the spontaneous VEGF expression observed in CTCL. Using a non-radioactive kinase assay with GST-Stat3 as substrate, we found that Jak3 was constitutively active in the malignant T cells but not in the non-malignant T cells (Figure 3a) . The constitutive activity of Jak3 was blocked by distinct Jak3 inhibitors (JAK3I1, JAK3I2 and Ag490), whereas an inhibitor of the epidermal growth factor receptor (EGFR), Ag1478, had no inhibitory effect (Figure 3a and b) . In parallel, the spontaneous VEGF production was inhibited by Jak3 inhibitors but not by the EGFR inhibitor or vehicle (DMSO) (Figure 3c ), indicating that Jak3 is indeed activated and involved in the VEGF expression in CTCL.
Because Jak3 activates Stat3 (Figure 3a and b) and Stat3 has been implicated in induction of VEGF expression in other cell types, 16, 21 we investigated if the spontaneous VEGF expression was induced through the activation of Stat3. However, downregulation of Stat3 expression with siRNA had no effect on the spontaneous VEGF production. Despite profound downregulation of Stat3, the VEGF production was unaffected (Figure 4d) . Figure 3 Constitutive Jak3 activity correlates with Stat3 phosphorylation and VEGF production. (a) Malignant (MF2000) and non-malignant (MF1928) T cells were incubated with 50 mg/ml JAK3I1 or vehicle (À) for 2 h. Then, Jak3 or Erk was immunopecipitated from the total cell lysates using rabbit anti-Jak3 or rabbit anti-Erk1/2 Abs, respectively. Precipitated Jak3 and Erk were incubated in kinase assay mix with or without the substrate GST-Stat3. Finally, the samples were subjected to SDS-PAGE and analyzed by Western blotting (WB) using anti-pYStat3-, anti-GST-and anti-Jak3-specific Abs. (b) Malignant and non-malignant (MF1885) T cells were incubated with JAK3I1 (50 mg/ml), JAK3I2 (50 mg/ml) or Ag1478 (200 ng/ml) for 2 h and Ag490 (100 mM) or vehicle (À) for 4 h. Subsequently, pYStat3 and total Stat3 levels were analyzed by WB. (c) MF2000 (1 Â 10 6 cells/sample) cells were washed and incubated with different concentrations (low, medium, high) of JAK3I1 (25, 50, 75 mg/ml), JAK3I2 (25, 50, 75 mg/ml), Ag1478 (100, 200, 300 ng/ml), Ag490 (50, 100, 150 mM) or the corresponding volume of vehicle (DMSO) for 6 h. Then, the supernatants were harvested and the VEGF concentration determined by ELISA. the VEGF promoter with a mutated Stat3 binding site (data not shown). Together, these data indicate that Jak3 induces VEGF expression independently of Stat3 in malignant CTCL T cells.
VEGF production correlates with constitutive JNK and AP-1 activity
When applied at medium concentrations, Jak3 inhibitors almost completely blocked the activation of the Jak3/Stat3 pathway, yet the VEGF synthesis was only suppressed by about 40% (Figure 3) . This observation suggests that other signaling pathways and transcription factors contribute to the spontaneous VEGF production. Given the presence of five putative AP-1 binding sites in the VEGF promoter (Figure 2) , the transcription factor AP-1 was a likely candidate. AP-1 is mainly composed of Jun/Jun homodimers (c-Jun, JunB, JunD) or Jun/Fos heterodimers (c-Fos, FosB, Fra-1, Fra-2) and, noteworthy, activation of c-Jun has previously been implicated in the induction of VEGF transcription. 22 Therefore, we estimated the binding activity of AP-1 to the VEGF promoter in the malignant and non-malignant T cells. This was performed by precipitating c-Jun from total cell lysates using a bio-oligo corresponding to the sequence from À1116 to À1136 bp in the VEGF promoter, which contains an AP-1 binding site (Figure 2 ). Constitutive binding of c-Jun to the AP-1 bio-oligo was found in the malignant T cells, whereas no binding was observed in the non-malignant T cells (Figure 4a ). Because the major regulators of c-Jun activity are the JNKs, we examined the impact of the well-characterized JNK inhibitor, Sp600125, on the binding of c-Jun to the AP-1 bio-oligo. As seen in Figure 4a , Sp600125 inhibited the binding of c-Jun to the AP-1 bio-oligo. Reversibly, PMA, an activator of JNK activity, increased the binding of c-Jun to the AP-1 bio-oligo (Figure 4a) . 23 These results strongly suggested that the constitutive binding of c-Jun was mediated by aberrant JNK activity. Indeed, we found high spontaneous JNK activity in the malignant T cells when compared to the non-malignant T cells (Figure 4b) . Moreover, treatment with Sp600125 resulted in an extensive inhibition of JNK activity in the malignant T cells, whereras only a small reduction of JNK activity was observed in the non-malignant T cells (Figure 4b) .
To investigate if the activity of the JNK/AP-1 pathway correlated with the VEGF production, we incubated the malignant T cells with various concentrations of Sp600125. Then, the total JNK activity in each sample was measured using a radioactive in vitro kinase assay with c-Jun as substrate. Further, the total JNK concentration in each sample was determined using a pan JNK ELISA kit. The specific JNK activity was calculated as the radioactivity incorporated into c-Jun (CPM) divided by the total amount of JNK protein (ng). Data are representative of three independent experiments. MF2000 cells were washed and incubated with given concentrations of Sp600125 for 6 h. Then, the supernatants were harvested and the VEGF concentration measured by ELISA. (c) MF2000 cells were incubated with Sp600125 (20 mM), Curcumin (20 mM), SB203580 (10 mM), JAK3I1 (50 mg/ml), JAK3I2 (50 mg/ml) or vehicle (À) for 2 h. Subsequently, the total JNK activity in each sample was measured using a radioactive in vitro kinase assay with c-Jun as substrate. The total JNK concentration in each sample was also determined using a pan JNK ELISA kit. The specific JNK activity was calculated as the radioactivity incorporated into c-Jun (CPM) divided by the total amount of JNK protein (ng).
Sp600125 inhibited profoundly the phosphorylation of c-Jun (Figure 5a ) and partially the VEGF production (Figure 5b ) at 5 and 10 mM, whereas the level of Stat3 phosphorylation was unaffected (Figure 5a ). Additionally, PMA not only induced both JNK and c-Jun activity, but also increased the VEGF production (data not shown).
In contrast to Sp600125, the Jak3 inhibitor, JAK3I1, did not influence the binding of c-Jun to the AP-1 bio-oligo (Figure 4a) . Likewise, Jak3 inhibitors, as well as the p38 inhibitor, SB203580, did not reduce the JNK activity, whereas Sp600125, expectedly, had a strong inhibitory effect (Figure 5c) . A minor increase in c-Jun phosphorylation and JNK activity was observed when using the p38 and Jak3 inhibitors, probably reflecting cellular stress (Figure 5a and c) . Together, these results suggest that constitutive activation of the JNK/AP-1 pathway contributes to the VEGF production of malignant CTCL T cells. As Jak3 inhibitors did not inhibit JNK or c-Jun activity, and, reversibly, Sp600125 did not suppress Jak3 activity, it is likely that Jak3 and the JNKs operate via two distinct signaling pathways.
Curcumin, an inhibitor of both Jak3 and JNK activity, almost completely blocks VEGF production Curcumin (diferuloylmethane) is a naturally occurring yellow pigment isolated from the rhizomes of the plant Curcuma longa (turmeric), which has been widely used in Indian medicine and culinary traditions since the second millennium BC. 24 In agreement with previous studies, we found that curcumin is a potent inhibitor of both JNK (Figure 5c ) 25 and Jak3 activity (Figure 6a) . 26 Accordingly, we expected curcumin to have a profound suppressive effect on VEGF production of malignant CTCL T cells. Indeed, curcumin almost completely blocked the spontaneous production of VEGF, whereas the p38 inhibitor, SB203580, essentially had no inhibitory effect (Figure 6b) . A similar effect was observed when combining Jak3 and JNK inhibitors (data not shown).
Expression and activity of HIF-1a, AP-2, Sp1 and Sp3 in CTCL HIF-1a is the major regulator of VEGF production in adaptive responses to changes in tissue oxygenation, but it is also constitutively expressed in many tumors resulting in spontaneous VEGF production. 27 However, whereas HIF-1a expression was observed when induced by treatment with CoCl 2 , we found no constitutive expression of HIF-1a in the malignant T cells (Figure 7a) . Consequently, HIF-1a does not seem to be involved in the spontaneous VEGF production in CTCL.
The transcription factor AP-2 (AP-2a) has been reported to inhibit VEGF expression in prostate cancer cells via direct transcriptional repression of the VEGF gene. 28 Moreover, there is a statistically significant association between loss of AP-2 expression and overexpression of VEGF in human gliomas. 29 We found that the non-malignant T cells expressed high levels of AP-2, whereas no expression of AP-2 was observed in the malignant T cells (Figure 7b ). Furthermore, a bio-oligo corresponding to the sequence from À85 to À65 bp of the VEGF promoter, which contains the proximal AP-2 response element (Figure 2 ), could precipitate AP-2 from the non-malignant but not the malignant T cells (Figure 7c , left). This shows that the non-malignant T cells express an active form of AP-2 capable of binding the VEGF promoter, whereas the malignant T cells do not, suggesting that loss of AP-2 expression could be implicated in VEGF expression in CTCL. The loss of AP-2 expression was Jak3 independent, as JAK3I1 did not induce expression of AP-2 in the malignant T cells (data not shown).
The four proximal Sp response elements (GC/GT boxes) in the VEGF promoter (Figure 2 ) play an important role in the regulation of VEGF transcription. Indeed, aberrant activity of Sp1 and/or Sp3 has been shown to mediate constitutive VEGF expression in some tumors. 8, 15 To estimate the binding activity of Sp1 and Sp3, we used a bio-oligo corresponding to the sequence from À61 to À81 bp of the VEGF promoter containing a consensus proximal Sp response element. Equal binding of both Sp1 and Sp3 to the Sp bio-oligo was observed in the malignant and non-malignant T cells (Figure 7c, right) . Accord- ingly, it does not appear that Sp1 or Sp3 induces VEGF production in the malignant T cells when compared to the non-malignant T cells.
Discussion
In this study, we show that VEGF is expressed in vitro and in vivo in CTCL. Furthermore, we provide evidence that aberrant activity of Jak3 and the JNKs, via distinct mechanisms, is responsible for the spontaneous VEGF production by malignant CTCL T cells. Additionally, we found that c-Jun phosphorylation and binding to a VEGF promoter element correlated with both JNK activity and VEGF production, indicating that the JNKs induce VEGF expression by increasing c-Jun/AP-1 activity. Activation of the JNK/AP-1 signaling pathway has previously been implicated in induction of VEGF transcription. 22 However, the JNKs have also been shown to promote VEGF expression through other mechanisms, such as increasing VEGF mRNA stability. 30 Hence, c-Jun/AP-1 activation might not be the only mechanism whereby the JNKs induce VEGF production in CTCL.
Jak3 has been suggested to play a key role in the transformation of CTCL T cells because Jak3 inhibitors trigger apoptosis and inhibit cell growth and spontaneous cytokine production of the malignant T cells. 19, 20, 31 Our present finding of high spontaneous tyrosine kinase activity of Jak3 strongly supports this hypothesis. The oncogene Stat3 is also persistently activated in the malignant T cells and is thought to be the primary target of Jak3-mediated transformation. 13, 32 As Stat3 has been shown to induce VEGF expression in other cell lines, it was possible that Jak3 induced VEGF production via activation of Stat3. 16, 21 However, using three different experimental methods, we found that the VEGF production was Stat3 independent. Recently, Gray et al. 33 have shown that pancreatic and prostate carcinoma cell lines treated with CoCl 2 (used to mimic hypoxia), or transfected with a constitutively active form of Src, require both HIF-1a expression and Stat3 activation to induce optimal VEGF expression. Interestingly, when HIF-1a DNA binding to the VEGF promoter is inhibited by a dominant-negative mutant of HIF-1a, the hypoxia-and Src-mediated VEGF production are almost completely blocked, despite activation and nuclear translocation of Stat3. 33 Intriguingly, we found no expression of HIF-1a in the malignant T cells. Thus, one explanation for the Stat3 independence could be that Stat3 requires coactivators such as HIF-1, which are not present in malignant T cells, to induce VEGF expression. Our results indicate that the transforming capacity of Jak3 in CTCL is not solely mediated through the activation of Stat3. Supporting this conclusion, it has previously been shown that whereas spontaneous IL-5 production by malignant CTCL T cells is mediated through a Jak3/Stat3-dependent pathway, spontaneous IL-6 production is mediated by a Jak3-dependent, Stat3-independent pathway. 31 Studies are in progress to identify novel Jak3-dependent, Stat3-independent signaling pathways in CTCL.
Downregulation of AP-2 (AP-2a) expression has been associated with the progression of melanoma, human gliomas, prostate, breast and colorectal cancer.
29,34-37 Interestingly, we found no expression of AP-2 in malignant CTCL T cells, whereas an active form of AP-2 was expressed in the non-malignant T cells. The tumor-suppressor-like role of AP-2 is directly linked to its ability to regulate the expression of genes involved in cell survival, adhesion, angiogenesis and invasion. 38 For instance, AP-2 has been shown to inhibit VEGF expression, suggesting that loss of AP-2 could contribute to VEGF production in CTCL. 28 AP-2 activity is also inversely correlated with the expression of matrix metalloproteinase-2 (MMP-2), and like VEGF production, MMP-2 expression increases with the progression of CTCL. 3, 39 Hence, loss of AP-2 might not only contribute to the VEGF production, but could be important in several aspects of CTCL progression.
VEGF is known to function as an autocrine growth factor in some tumors. 6 However, preliminary immunohistochemical and flow cytometric analyses showed no expression of VEGF receptor 1 (VEGFR1) or VEGFR2 on the malignant T cells and only a weak expression of VEGFR3 (data not shown). Moreover, neutralization of VEGF activity in the cell culture supernatant, using a pan-VEGF neutralizing antibody, had no effect on the proliferation of the malignant T cells, indicating that VEGF is not an autocrine growth factor in CTCL (data not shown).
Biopsies from CTCL patients exhibit stage-dependent increase in angiogenesis. 3 Our results indicate that VEGF production is an early event in CTCL progression. Indeed, a very high frequency of VEGF-positive cells (490%) was seen in five of 11 patients with early disease, suggesting that VEGF is involved in the early stages of angiogenesis in CTCL. However, given the highly angiogenic properties and diverse effects of VEGF in cancer development, it is likely that VEGF also plays a key role in the angiogenesis and disease progression in later stages of CTCL. Consequently, inhibition of VEGF-inducing pathways or neutralization of VEGF itself could represent novel strategies in the treatment of early and advanced CTCL. Accordingly, bevacizumab (Avastin), a humanized VEGF neutralizing mAb, which has shown low toxicity and increased survival in combinatorial treatment of patients with advanced cancer, might be useful in the treatment of CTCL. 40 Furthermore, curcumin, which we have identified as a potent inhibitor of VEGF production by the malignant T cells, might also be useful in CTCL therapy. Notably, clinical phase I trials show that curcumin is non-toxic even when administered at very high doses for long periods of time. 41 In conclusion, we show that malignant CTCL T cells produce high levels of VEGF through Jak3-and JNK-dependent signal pathways. Thus, we have identified novel potential targets for future therapy of CTCL.
